Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsTYPTF 3-Year EPS without NRI Growth Rate is 69.60% as of Dec. 2025, which is 610% above its 10-year median of 9.80. The stock has 5 warning signs investors should review. Among 1,161 Biotechnology companies, Entropy Neurodynamics ranks better than 92.85% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 69.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 37.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Entropy Neurodynamics was 69.60% per year. The lowest was -16.90% per year. And the median was 9.80% per year.
Entropy Neurodynamics (OTCPK:TYPTF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Entropy Neurodynamics 3-Year EPS without NRI Growth Rate Related Terms
TYPTF vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Entropy Neurodynamics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's 3-Year EPS without NRI Growth Rate falls into.
Entropy Neurodynamics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 69.60% mean?
Entropy Neurodynamics (TYPTF) has a 3-Year EPS without NRI Growth Rate of 69.60% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Entropy Neurodynamics and its competitors. This is 610% above median its historical median of 9.80. According to the industry distribution chart, Entropy Neurodynamics ranks #83 out of 1161 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Entropy Neurodynamics' 3-Year EPS without NRI Growth Rate too high?
Entropy Neurodynamics' current 3-Year EPS without NRI Growth Rate of 69.60% is 610% above median its 10-year median of 9.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Entropy Neurodynamics' value of 69.60% is 329.6% above this industry median. Based on the distribution chart, Entropy Neurodynamics ranks #83 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Entropy Neurodynamics' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #83 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This places Entropy Neurodynamics in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Entropy Neurodynamics' value of 69.60% is 329.6% above this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 16.20, Entropy Neurodynamics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entropy Neurodynamics's current 3-Year EPS without NRI Growth Rate of 69.60% is 329.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Entropy Neurodynamics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entropy Neurodynamics's current 3-Year EPS without NRI Growth Rate is 69.60%, which is 610% above median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 25% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 69.60%, which is 610% above median its 10-year median of 9.80 and 329.6% above the Biotechnology industry median of 16.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current 3-Year EPS without NRI Growth Rate is 69.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TYPTF has been successfully added to your 
